treating patients with stage iv lung adenocarcinoma without actionable oncogenic drivers
Published 6 years ago • 206 plays • Length 2:50Download video MP4
Download video MP3
Similar videos
-
2:33
treating nsclc patients without an actionable oncogenic driver
-
7:50
case 4: stage iv adenocarcinoma without genetic driver
-
4:44
treating advanced lung cancer in patients without driver mutations
-
30:32
2023 best of lung: targeted therapies in lung cancer
-
3:24
nondriver lung adenocarcinoma: treatment considerations
-
1:17
questioning when to start immunotherapy for patients with oncogenic drivers
-
2:52
pathology of stage iv lung adenocarcinoma
-
3:19
case 4: treating stage iv nsclc with novel approaches
-
2:19
patient summary: egfr-mutant stage 4 lung adenocarcinoma
-
25:26
locally advanced nsclc: combination therapy with targeted and immunotherapy agents
-
59:19
precision oncology in early-stage lung cancer, with adjuvant egfr-targeted therapy leading the way
-
26:33
targeted therapy of lung cancer with or without driver mutations
-
1:00:18
improving clinical care with newer better therapies for targeting actionable gene fusions in nsclc
-
0:50
targeted option for non-small cell lung cancer #2023 #oncology #lungcancer
-
2:20
selecting patients with nsclc who benefit from immunotherapy or targeted therapies
-
44:56
advanced nsclc: refining clinical pathways in the rapidly evolving therapeutic landscape
-
6:40:28
full video ondemand -targeted therapies patient forum 2022 - for those living with lung cancer
-
16:35
heterogeneity of nsclc and precipitating oncogenic driver mutations
-
1:13
targeting oncogenes in nsclc